Must Be Climate Change Deniers
LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found.
The carbon output of the sector as a whole was found to eclipse emissions from the forestry and paper industry, which are widely regarded as some of the most carbon-intensive industries.
The analysis - which excluded the substantial carbon impact of government labs, universities, and healthcare systems - found that the total carbon impact of 231 publicly-listed biopharma companies increased 15% to 227 million metric tons of carbon dioxide equivalent (tCO2-e) in 2021 from 197 million in 2020.